Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time
CanPREDDICT
CanPREDDICT: Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time
1 other identifier
observational
2,602
1 country
25
Brief Summary
This study will follow 2500 prevalent Chronic Kidney Disease (CKD) patients with Glomerular Filtration Rate (GFR) from 15-45 ml/min for 30 months with serial measurements every 6 months and subsequent annual chart review up to 60 months. This observational study will analyze the demographics, clinical status, medications and blood and urine samples of these patients and study the conventional biochemical, hormonal and metabolic parameters assessing which underlying biomarkers reflect the processes involved with disease progression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2008
Longer than P75 for all trials
25 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2008
CompletedFirst Submitted
Initial submission to the registry
January 20, 2009
CompletedFirst Posted
Study publicly available on registry
January 22, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2014
CompletedNovember 28, 2013
November 1, 2013
6.5 years
January 20, 2009
November 27, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Renal Replacement Therapy
Renal Replacement Therapy is defined as dialysis start or transplantation.
6 monthly for 3 years, annually up to 5 years
Cardiovascular events
Cardiovascular events are defined as myocardial infarction, ischemic and hemorrhagic stroke, coronary revascularization, congestive heart failure, peripheral bypass and gangrenes, adjudicated by a nephrologist, cardiologist and neurologist.
6 monthly for 3 years, annually up to 5 years
Death
Deaths are reported with source documentation and adjudicated for ischemic or congestive cardiovascular death, other cardiovascular death, non-cardiovascular death and unknown cause of death.
6 monthly for 3 years, annually up to 5 years
Study Arms (3)
Bioimpedance sub-study cohort
Funded by a grant from Kidney Foundation of Canada, Dr. Catherine Clase initiated a bioimpedance sub-study across 7 centres and recruited n=416 within the CANPREDDICT population. The study uses bioimpedance measurements to assess volume status to determine the multivariable relationship between baseline volume overload and subsequent cardiovascular events. Subjects are followed at 6 months intervals for 2 years.
Ethnic enrichment cohort
Additional recruitment initiated and funded by the Principal Investigator, Adeera Levin for enriching the ethnic representation within the Canadian cohort on South Asian and Oriental Asian was completed from Sept 2012 to June 2013, n=53.
Original CanPreddict cohort
The original CanPreddict cohort was recruited from Jun 2008 - Oct 2009 has 2544 CKD patients across Canada.
Eligibility Criteria
Nephrology Clinics across Canada
You may qualify if:
- Patients currently seen by a nephrologist, or referred for evaluation of CKD
- GFR between 15-45 ml/min
- Adults 19 years (depending on age of consent in province) or older
- At pediatric sites study participants will be eligible to participate at age 15 or older
You may not qualify if:
- Organ transplant recipient
- Life expectancy less than 12 months
- Acute Vasculitis
- Amputation (readings are inaccurate)
- Any battery operated or electronic implanted device (such as pacemaker or implanted defibrillator - potential electrical hazard)
- Pregnant women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (25)
Foothills Hospital
Calgary, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
Penticton Regional Hospital
Penticton, British Columbia, Canada
BC Children's Hospital
Vancouver, British Columbia, Canada
St. Paul's Hospital
Vancouver, British Columbia, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
St. Boniface Hospital
Winnipeg, Manitoba, Canada
Eastern Regional Health Authority, Health Sciences Centre
St. John's, Newfoundland and Labrador, Canada
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
Cape Breton District Health Authority
Sydney, Nova Scotia, Canada
St Joseph's Hospital
Hamilton, Ontario, Canada
Kingston General Hospital
Kingston, Ontario, Canada
London Health Science Centre- University Campus
London, Ontario, Canada
London Health Science Centre- Victoria Campus
London, Ontario, Canada
York Central
Oak Ridges, Ontario, Canada
University of Ottawa
Ottawa, Ontario, Canada
Timmins & District Hospital
Timmins, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
Sunnybrook Hospital
Toronto, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
Charles Le Moyne Hospital
Greenfield Park, Quebec, Canada
Hôpital du Sacré-Coeur
Montreal, Quebec, Canada
Maisonneuve-Rosemont Hopital
Montreal, Quebec, Canada
Royal Victoria Hospital
Montreal, Quebec, Canada
CHUQ: L'Hôtel-Dieu de Québec
Québec, Quebec, Canada
Related Publications (3)
Levin A, Rigatto C, Brendan B, Madore F, Muirhead N, Holmes D, Clase CM, Tang M, Djurdjev O; CanPREDDICT investigators. Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT). BMC Nephrol. 2013 Jun 11;14:121. doi: 10.1186/1471-2369-14-121.
PMID: 23758910RESULTLevin A, Rigatto C, Barrett B, Madore F, Muirhead N, Holmes D, Clase C, Tang M, Djurdjev O. (2012). Canadian study of prediciont of death, dialysis and interim cardiovascular events: CanPREDDICT: Biomarkers improve prediction of one year outcomes in chronic kidney disease cohort. Clinical studies in CKD. Nephrology Dialysis Transplantation, 27(suppl 2), ii63-ii65.
RESULTLevin A, Rigatto C, Barrett B, Madore F, Muirhead N, Holmes D, Clase CM, Tang M, Djurdjev O; CanPREDDICT Investigators. Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort. Nephrol Dial Transplant. 2014 May;29(5):1037-47. doi: 10.1093/ndt/gft479. Epub 2013 Dec 26.
PMID: 24371297RESULT
Biospecimen
Serum,Plasma,Urine, DNA and RNA
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Adeera Levin
University of British Columbia
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 20, 2009
First Posted
January 22, 2009
Study Start
June 1, 2008
Primary Completion
December 1, 2014
Study Completion
December 1, 2014
Last Updated
November 28, 2013
Record last verified: 2013-11